^
Association details:
| Biomarker: | KRAS G12V |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor) + defactinib (VS-6063) (FAK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 2 Study of VS-6766 Alone and In Combination with Defactinib in Non-Small Cell Lung Cancer (NSCLC) Estudio en fase II de VS-6766 como agente único y en combinación con defactinib en el cáncer de pulmón no microcítico (CPNM)
Excerpt:
...Subjects must have a known KRAS mutation determined using a validated next-generationsequencing (NGS) and/or polymerase chain reaction (PCR) testing method prior to enrollment. ...
Trial ID:
Source:
Title:
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
Excerpt:
...- Known KRAS or BRAF mutation...
Trial ID:
More C2 evidence
Source:
Title:
Phase I Trial of Defactinib and VS-6766.
Excerpt:
...Histologically or cytologically proven advanced non-small-cell lung cancer (NSCLC) with a documented KRAS mutation, refractory to conventional treatment, or for which...
Trial ID:
Less C2 evidence
Source:
Title:
1425 - Synergistic antitumor efficacy of the dual RAF/MEK inhibitor VS-6766 with FAK inhibition for treatment of RAS-dependent solid tumors
Published date:
03/10/2021
Excerpt:
VS-6766 with defactinib also showed clinical activity in KRAS-G12V mt NSCLC.
Trial ID:
Source:
Title:
CT019-A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC
Published date:
03/10/2021
Excerpt:
The combination of VS-6766 and defactinib treatment in cohorts of patients with NSCLC pre-treated with chemotherapy and immunotherapy has shown anti-tumour activity in subsets of patients with KRAS mutated NSCLC, in particular those with tumours harbouring KRAS G12V mutations.
Trial ID:
Source:
Title:
Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the American Association for Cancer Research 2020 Virtual Annual Meeting I
Published date:
04/27/2020
Excerpt:
...investigator-initiated Phase 1 clinical study investigating VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant advanced solid tumors....The preliminary data reported in the study suggest that a novel intermittent dosing schedule of RAF/MEK and FAK inhibitor combination therapy has promising clinical activity in patients with KRAS mutant LGSOC and KRASG12V mutant NSCLC, including patients previously treated with a MEK inhibitor.
